Xilio Therapeutics (XLO)
8.19
-0.12 (1.44%)
Upcoming Events
Latest Headlines
Form EFFECT Xilio Therapeutics, Inc.
June 1, 2026 6:08 AM - SEC Filing
Form S-3/A Xilio Therapeutics, Inc.
May 27, 2026 5:30 PM - SEC Filing
Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2026 4:45 PM - SEC Filing
Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.
May 15, 2026 4:36 PM - SEC Filing
Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:32 PM - SEC Filing
Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: Sirenia Capital Management LP
May 15, 2026 8:07 AM - SEC Filing
Xilio Therapeutics (XLO) files $250M mixed shelf
May 12, 2026 7:57 AM - StreetInsider
Form S-3 Xilio Therapeutics, Inc.
May 12, 2026 7:49 AM - SEC Filing
Form 10-Q Xilio Therapeutics, Inc. For: Mar 31
May 12, 2026 7:41 AM - SEC Filing
Form 8-K Xilio Therapeutics, Inc. For: May 12
May 12, 2026 7:35 AM - SEC Filing
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 12, 2026 7:30 AM - Globe NewsWire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026 4:30 PM - StreetInsider
Form ARS Xilio Therapeutics, Inc. For: Dec 31
April 28, 2026 5:07 PM - SEC Filing
Form DEF 14A Xilio Therapeutics, Inc. For: Jun 10
April 28, 2026 5:02 PM - SEC Filing
Xilio presents preclinical data for cancer treatment XTX601 at AACR
April 17, 2026 4:01 PM - StreetInsider
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 17, 2026 4:01 PM - StreetInsider
Form 4 Xilio Therapeutics, Inc. For: Apr 15 Filed by: Blanchard Cheryl R
April 16, 2026 5:12 PM - SEC Filing
Form 3 Xilio Therapeutics, Inc. For: Apr 15 Filed by: Blanchard Cheryl R
April 16, 2026 5:11 PM - SEC Filing
Xilio Therapeutics adds Cheryl Blanchard to board of directors
April 16, 2026 11:42 AM - StreetInsider
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026 11:42 AM - Globe NewsWire
Form 8-K Xilio Therapeutics, Inc. For: Apr 15
April 16, 2026 7:35 AM - SEC Filing
Xilio Therapeutics adds Cheryl Blanchard to board, Rossi steps down
April 16, 2026 7:32 AM - StreetInsider
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026 7:31 AM - StreetInsider
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026 4:30 PM - StreetInsider
Form 4 Xilio Therapeutics, Inc. For: Mar 26 Filed by: Shannon James Samuel
March 30, 2026 5:30 PM - SEC Filing
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 24, 2026 9:50 AM - Globe NewsWire
Form S-8 Xilio Therapeutics, Inc.
March 23, 2026 7:48 AM - SEC Filing
Form 10-K Xilio Therapeutics, Inc. For: Dec 31
March 23, 2026 7:41 AM - SEC Filing
Form 8-K Xilio Therapeutics, Inc. For: Mar 23
March 23, 2026 7:33 AM - SEC Filing
Xilio Therapeutics reports Q4 2025 results, extends cash runway to 2027
March 23, 2026 7:31 AM - StreetInsider
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026 7:30 AM - StreetInsider
Xilio Therapeutics to present preclinical data on CLDN18.2 therapy at AACR
March 17, 2026 4:45 PM - StreetInsider
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026 4:45 PM - StreetInsider
Form 8-K Xilio Therapeutics, Inc. For: Mar 12
March 12, 2026 8:35 AM - SEC Filing
Xilio Therapeutics implements 1-for-14 reverse stock split
March 12, 2026 8:30 AM - StreetInsider
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 12, 2026 8:30 AM - StreetInsider
Form 8-K Xilio Therapeutics, Inc. For: Mar 09
March 9, 2026 8:01 AM - SEC Filing
Full Article List
